Join
Live feed
·
PRReleasevia Quantisnow
PLUS THERAPEUTICS Inc. logo

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

ByQuantisnow·Wall Street's wire, on your screen.
PSTV· PLUS THERAPEUTICS Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PSTV (PLUS THERAPEUTICS Inc.) and more on Quantisnow.